A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia

Insomnia affects 4.4–4.8% of the world’s population, but because the effect of hypnotic drugs is limited and may cause harmful side-effects, scientists are turning their attention to developing drugs that act on the orexin system. Daridorexant, a selective dual-orexin receptor antagonist (DORA), has...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemichód, Wojciech, Grabowska, Karolina, Kurowska, Antonina, Biała, Grażyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502995/
https://www.ncbi.nlm.nih.gov/pubmed/36144776
http://dx.doi.org/10.3390/molecules27186041
_version_ 1784795853930627072
author Ziemichód, Wojciech
Grabowska, Karolina
Kurowska, Antonina
Biała, Grażyna
author_facet Ziemichód, Wojciech
Grabowska, Karolina
Kurowska, Antonina
Biała, Grażyna
author_sort Ziemichód, Wojciech
collection PubMed
description Insomnia affects 4.4–4.8% of the world’s population, but because the effect of hypnotic drugs is limited and may cause harmful side-effects, scientists are turning their attention to developing drugs that act on the orexin system. Daridorexant, a selective dual-orexin receptor antagonist (DORA), has exhibited promising results in both animal and human studies. Its activity was evaluated based on the physiology-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects including deprivation of next-morning residual effects. In this manuscript we conducted a comprehensive review of daridorexant including pharmacodynamics, animal and human research, pharmacokinetics and safety.
format Online
Article
Text
id pubmed-9502995
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95029952022-09-24 A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia Ziemichód, Wojciech Grabowska, Karolina Kurowska, Antonina Biała, Grażyna Molecules Review Insomnia affects 4.4–4.8% of the world’s population, but because the effect of hypnotic drugs is limited and may cause harmful side-effects, scientists are turning their attention to developing drugs that act on the orexin system. Daridorexant, a selective dual-orexin receptor antagonist (DORA), has exhibited promising results in both animal and human studies. Its activity was evaluated based on the physiology-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects including deprivation of next-morning residual effects. In this manuscript we conducted a comprehensive review of daridorexant including pharmacodynamics, animal and human research, pharmacokinetics and safety. MDPI 2022-09-16 /pmc/articles/PMC9502995/ /pubmed/36144776 http://dx.doi.org/10.3390/molecules27186041 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ziemichód, Wojciech
Grabowska, Karolina
Kurowska, Antonina
Biała, Grażyna
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title_full A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title_fullStr A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title_full_unstemmed A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title_short A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
title_sort comprehensive review of daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502995/
https://www.ncbi.nlm.nih.gov/pubmed/36144776
http://dx.doi.org/10.3390/molecules27186041
work_keys_str_mv AT ziemichodwojciech acomprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT grabowskakarolina acomprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT kurowskaantonina acomprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT białagrazyna acomprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT ziemichodwojciech comprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT grabowskakarolina comprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT kurowskaantonina comprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia
AT białagrazyna comprehensivereviewofdaridorexantadualorexinreceptorantagonistasnewapproachforthetreatmentofinsomnia

Ejemplares similares